What is Omnicell's gross profit margin?

What were the key takeaways from Omnicell’s earnings call?

What does Omnicell do and what are its main business segments?

What were the key takeaways from Omnicell's earnings call?

What guidance did Omnicell's management provide for the next earnings period?

What factors drove the changes in Omnicell's revenue and profit?

What is Omnicell's latest dividend and current dividend yield?

What is the market's earnings forecast for Omnicell next quarter?

- **Revenue Beat**: Q3 revenue $311M (+10% YoY), Non-GAAP EPS $0.51 vs. $0.56 prior year. Full-year guidance raised to $1.177B-$1.187B.
- **OmniSphere Expansion**: 60+ customers migrating to cloud platform; early adopters report efficiency gains. HITRUST-certified security.
- **Tariff Mitigation**: $6M Q3 impact, 2025 total $15M. 2026 actions to reduce impact below Q4 2025 run rate.
- **Innovation Push**: Modular robots, AI-driven pharmacy solutions, and ASHP 2025 product showcase.
- **340B Growth**: Over 50% new contracts from existing customers, ARR $610M-$630M.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $311 million, up 10% YoY, driven by point-of-care solutions like XTExtend. Non-GAAP EPS was $0.51, exceeding expectations.
- **OmniSphere Momentum**: Cloud-based platform achieved HITRUST certification, with early adopters and plans for full customer migration. Expansion into outpatient settings and government facilities.
- **Strategic Pillars**: Market expansion (nursing units, ORs), service contracts (subscriptions, software), and technology acceleration (AI, robotics). Completed $75M stock buyback, reducing shares by 5%.
- **Innovation Focus**: Autonomous pharmacy vision with AI and robotics; new compounding robot in limited release. ASHP 2025 showcase for new innovations.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 GAAP EPS $0.12, Non-GAAP EPS $0.51. Gross margin 44.2%. Free cash flow $14M, down from $27M prior quarter. Tariffs impacted Q3 profitability by $6M, expected to continue in Q4.
- **Guidance Update**: Full-year revenue raised to $1.177B-$1.187B, up from $1.13B-$1.16B. Non-GAAP EBITDA $140M-$146M, up from $130M-$145M. ARR $610M-$630M.
- **Tariff Mitigation**: Supply chain diversification to reduce 2026 impact. Q4 revenue $306M-$316M, EBITDA $37M-$43M.

**【Q&A Highlights】**
- **Robotics & Hardware**: Exploring humanoid robots for pharmacy; smaller, modular dispensing robots in development. Robotics integration into current products for efficiency.
- **OmniSphere Adoption**: 60+ customers on OmniCenter migrating to OmniSphere. Early adopters report improved visibility and efficiency.
- **IV Opportunity**: Ballad Health win for IV workflow solutions. Hub-and-spoke model based on health system size and throughput needs.
- **340B Growth**: Over half of new 340B contracts from existing customers. Regulatory headwinds offset by hospital focus on ROI, ARR growth expected.
- **Sales Cycle**: Consistent pipeline momentum, no significant cycle changes. Focus on point-of-care products with limited release compounding robot.
- **Tariff Impact**: Q3/Q4 $6M net impact, 2025 total $15M. 2026 mitigation efforts to reduce impact below Q4 2025 run rate.

OMCL

OMCL fundamentals

You can ask Aime